Last reviewed · How we verify
Combivir+Kaletra
This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients.
At a glance
| Generic name | Combivir+Kaletra |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination therapy (NRTI + protease inhibitor) |
| Target | HIV reverse transcriptase and HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Combivir (lamivudine/zidovudine) contains two nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while Kaletra (lopinavir/ritonavir) is a protease inhibitor combination that blocks HIV protease. Together, they target two critical steps in the HIV replication cycle to reduce viral load and slow disease progression.
Approved indications
- HIV-1 infection in treatment-naïve or treatment-experienced patients
Common side effects
- Nausea
- Diarrhea
- Headache
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
- Pancreatitis
- Peripheral neuropathy
Key clinical trials
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (PHASE2)
- Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combivir+Kaletra CI brief — competitive landscape report
- Combivir+Kaletra updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI